Key result
Retrospective audit evaluates SGLT2 inhibitor prescribing patterns in HFpEF beyond diabetes.
Why the study?
Despite proven cardiovascular benefits of SGLT2 inhibitors irrespective of glycemic status in HFpEF, prescribing patterns, particularly beyond diabetes, needed evaluation.
What are the prescribing patterns of SGLT2 inhibitors in patients with HFpEF, particularly beyond diabetes?
Observational
What are the prescribing patterns of SGLT2 inhibitors in patients with HFpEF, particularly beyond diabetes?
Answers are grounded in this paper and cite their sources.
Adds cohort data on SGLT2 inhibitors in HFpEF; leaves open confirmation by randomized trials.
Heart failure with preserved ejection fraction (HFpEF) constitutes a substantial and increasing proportion of heart failure cases worldwide, with historically limited evidence-based therapeutic options. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, initially developed for the management of type 2 diabetes mellitus, have demonstrated significant cardiovascular benefits, including reductions in heart failure hospitalizations and improvement in functional outcomes, irrespective of glycemic status. This retrospective audit aimed to evaluate prescribing patterns of SGLT2 inhibitors in patients with HFpEF, with particular emphasis on their utilization beyond diabetes.
No takes yet. Share an insight, caveat, or question.
Nazeem et al. (2026) conducted an observational in Heart failure with preserved ejection fraction (HFpEF). SGLT2 inhibitors was evaluated on Prescribing patterns of SGLT2 inhibitors. This retrospective audit aimed to evaluate prescribing patterns of SGLT2 inhibitors in patients with HFpEF, with particular emphasis on their utilization beyond diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: